The long-predicted deal-making boom in Big Pharma started with a bang on Wednesday, as Bristol-Myers Squibb announced it will buy Celgene in a cash and stock transaction worth $74 billion. The deal values Celgene at $102.43 a share—54% higher than
read moreThe US Food and Drug Administration has approved the new treatment Sprycel for children one year of age and older, facing a type of blood cancer known as Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) when used in combination with
read moreEntry for the PharmaTimes International Clinical Researcher of the Year competition will close for entry on the 31st January. Entries are already surpassing this time last year so enter now and join them. More: Don’t miss out on the chance
read moreExonate has successfully fundraised £1.5 million to accelerate development of its lead product – an eye drop treatment for retinal neovascular diseases. More: Exonate fundraises £1.5 million Source: News
read moreBringing an end to a four-year partnership, Sanofi has terminated its agreement with MyoKardia to jointly develop small-molecule therapeutics, targeting genetic mutations associated with certain heart diseases. More: Sanofi and MyoKardia end heart disease drug collaboration Source: News
read moreNHS England is urging patients to cancel appointments rather than just not show up, after news emerged that more than 15 million general practice appointments are being wasted each year because patients do not turn up and fail to warn
read more© 1994 - 2026 B.M. Pharmaceuticals